Protein Sciences has announced the publication of clinical trial results comparing Flublok® Quadrivalent – the quadrivalent version of Flublok® influenza vaccine – to a traditional egg-based quadrivalent inactivated vaccine. The data published in the June 22 issue of the New England Journal of Medicine show that Flublok Quadrivalent provided significantly improved protection against laboratory confirmed influenza illness in older adults.

“This study shows that Flublok® Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than
standard-dose quadrivalent influenza vaccine produced with traditional technology,” said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences.